Definium Therapeutics (NASDAQ: DFTX) announced that the first patient has been dosed in Ascend, its second phase 3 study evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE